ABSTRACT
Adolescent transplant recipients are at risk for nonadherence, development of de novo donor-specific antibody (dnDSA), and allograft loss. Belatacept, a selective T cell costimulatory blocker, is associated with reduced dnDSA, improved renal function, and prolonged allograft survival when compared to calcineurin inhibitor-based regimens in adults; however, its use in children is scant. Three adolescents were initiated on belatacept between August 2017 and September 2018 at the time of kidney transplantation. Selection criteria included age ≥ 14 and EBV IgG + serostatus. Intraoperative alemtuzumab and methylprednisolone were given as induction therapy. Tailored maintenance therapy included steroid-free belatacept and sirolimus for two patients. One patient was initially maintained steroid-free on belatacept and belimumab, an inhibitor of B cell activating factor to treat concurrent systemic lupus erythematous; steroids were added subsequently. Renal function, biopsy-proven rejection, dnDSA, allograft survival, infection, nonadherence, and proteinuria were monitored. Renal function was 86, 73, 52 mL/min/1.73 m2 at 20, 20, and 8 months, respectively. There was 100% adherence to therapy and no development of dnDSA. All patients had treatable infections. One developed steroid-responsive acute cellular rejection. Belatacept-based regimens can be tailored for adolescent recipients with good short-term clinical outcomes.
Subject(s)
Kidney Transplantation , Abatacept/therapeutic use , Adolescent , Adult , Calcineurin Inhibitors , Child , Graft Rejection/drug therapy , Graft Rejection/etiology , Graft Rejection/prevention & control , Graft Survival , Humans , Immunosuppressive Agents/therapeutic useABSTRACT
Background: Currently, there is no standardized approach for determining psychosocial readiness in pediatric transplantation. We examined the utility of the Psychosocial Assessment of Candidates for Transplantation (PACT) to identify pediatric kidney transplant recipients at risk for adverse clinical outcomes. Methods: Kidney transplant patients <21-years-old transplanted at Duke University Medical Center between 2005 and 2015 underwent psychosocial assessment by a social worker with either PACT or unstructured interview, which were used to determine transplant candidacy. PACT assessed candidates on a scale of 0 (poor candidate) to 4 (excellent candidate) in areas of social support, psychological health, lifestyle factors, and understanding. Demographics and clinical outcomes were analyzed by presence or absence of PACT and further characterized by high (≥3) and low (≤2) scores. Results: Of 54 pediatric patients, 25 (46.3%) patients underwent pre-transplant evaluation utilizing PACT, while 29 (53.7%) were not evaluated with PACT. Patients assessed with PACT had a significantly lower percentage of acute rejection (16.0 vs. 55.2%, p = 0.007). After adjusting for HLA mismatch, a pre-transplant PACT score was persistently associated with lower odds of acute rejection (Odds Ratio 0.119, 95% Confidence Interval 0.027-0.52, p = 0.005). In PACT subsection analysis, the lack of family availability (OR 0.08, 95% CI 0.01-0.97, p = 0.047) and risk for psychopathology (OR 0.34, 95% CI 0.13-0.87, p = 0.025) were associated with a low PACT score and post-transplant non-adherence. Conclusions: Our study highlights the importance of standardized psychosocial assessments and the potential use of PACT in risk stratifying pre-transplant candidates.
ABSTRACT
Fanconi syndrome, also known as the DeToni, Debré, Fanconi syndrome is a global dysfunction of the proximal tubule characterized by glucosuria, phosphaturia, generalized aminoaciduria, and type II renal tubular acidosis. Often there is hypokalemia, sodium wasting, and dehydration. In children, it typically is caused by inborn errors of metabolism, principally cystinosis. In adults, it is mainly caused by medications, exogenous toxins, and heavy metals. Treatment consists of treating the underlying cause and replacing the lost electrolytes and volume.
Subject(s)
Fanconi Syndrome/diagnosis , Fanconi Syndrome/therapy , Child , Diagnosis, Differential , HumansABSTRACT
The original version of this article unfortunately contained a mistake. The subtitle "A Midwest Pediatric Nephrology Consortium (MWPNC) study" was missing. The correct title including subtitle is given above.
ABSTRACT
BACKGROUND AND OBJECTIVES: Steroid-resistant nephrotic syndrome (SRNS) due to focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is a leading cause of end-stage kidney disease in children. Recurrence of primary disease following transplantation is a major cause of allograft loss. The clinical determinants of disease recurrence are not completely known. Our objectives were to determine risk factors for recurrence of FSGS/MCD following kidney transplantation and factors that predict response to immunosuppression following recurrence. METHODS: Multicenter study of pediatric patients with kidney transplants performed for ESKD due to SRNS between 1/2006 and 12/2015. Demographics, clinical course, and biopsy data were collected. Patients with primary-SRNS (PSRNS) were defined as those initially resistant to corticosteroid therapy at diagnosis, and patients with late-SRNS (LSRNS) as those initially responsive to steroids who subsequently developed steroid resistance. We performed logistic regression to determine risk factors associated with nephrotic syndrome (NS) recurrence. RESULTS: We analyzed 158 patients; 64 (41%) had recurrence of NS in their renal allograft. Disease recurrence occurred in 78% of patients with LSRNS compared to 39% of those with PSRNS. Patients with MCD on initial native kidney biopsy had a 76% recurrence rate compared with a 40% recurrence rate in those with FSGS. Multivariable analysis showed that MCD histology (OR; 95% CI 5.6; 1.3-23.7) compared to FSGS predicted disease recurrence. CONCLUSIONS: Pediatric patients with MCD and LSRNS are at higher risk of disease recurrence following kidney transplantation. These findings may be useful for designing studies to test strategies for preventing recurrence.
Subject(s)
Glomerulosclerosis, Focal Segmental/complications , Graft Rejection/diagnosis , Kidney Transplantation/adverse effects , Kidney/pathology , Nephrosis, Lipoid/complications , Nephrotic Syndrome/therapy , Adolescent , Adult , Biopsy , Child , Child, Preschool , Drug Resistance , Female , Glomerulosclerosis, Focal Segmental/drug therapy , Glomerulosclerosis, Focal Segmental/pathology , Glucocorticoids/pharmacology , Glucocorticoids/therapeutic use , Graft Rejection/etiology , Humans , Infant , Infant, Newborn , Male , Nephrosis, Lipoid/drug therapy , Nephrosis, Lipoid/pathology , Nephrotic Syndrome/etiology , Preoperative Period , Prognosis , Recurrence , Retrospective Studies , Risk Factors , Young AdultABSTRACT
NE (typhlitis) is a potentially life-threatening disease process characterized by bowel wall edema, ulceration, and hemorrhage in an immunosuppressed patient. We report a 15-year-old boy status post deceased donor renal transplantation who presented with fever, abdominal pain, and diarrhea. Laboratory studies revealed neutropenia 5 days prior to admission, and abdominal computed tomography revealed bowel wall thickening in the cecum consistent with NE. He was treated with piperacillin-tazobactam and gentamicin and recovered. To our knowledge, this is the first report of a case of NE in a pediatric kidney transplant recipient.
Subject(s)
Enterocolitis, Neutropenic/diagnosis , Kidney Transplantation , Postoperative Complications/diagnosis , Adolescent , Enterocolitis, Neutropenic/etiology , Humans , MaleABSTRACT
BACKGROUND: Primary vesicoureteral reflux (PVUR) is the most common malformation of the kidney and urinary tract, and reflux nephropathy is a major cause of chronic kidney disease in children. Recently, we reported mutations in the tenascin XB gene (TNXB) as a cause of PVUR with joint hypermobility. METHODS: To define the role of rare variants in tenascin genes in the etiology of PVUR, we screened a cohort of patients with familial PVUR (FPVUR) and non-familial PVUR (NFPVUR) for rare missense variants inTNXB and the tenascin C gene (TNC) after excluding mutations in ROBO2 and SOX17. RESULTS: The screening procedure identified 134 individuals from 112 families with PVUR; two families with mutations in ROBO2 were excluded from further analysis. Rare missense variants in TNXB were found in the remaining 110 families, of which 5/55 (9%) families had FPVUR and 2/55 (4%) had NFPVUR. There were no differences in high-grade reflux or renal parenchymal scarring between patients with and without TNXB variants. All patients with TNXB rare variants who were tested exhibited joint hypermobility. Overall we were able to identify causes of FPVUR in 7/57 (12%) families (9% in TNXB and 3% in ROBO2). CONCLUSIONS: In conclusion, the identification of a rare missense variant in TNXB in combination with a positive family history of VUR and joint hypermobility may represent a non-invasive method to diagnose PVUR and warrants further evaluation in other cohorts.
Subject(s)
Mutation, Missense , Tenascin/genetics , Vesico-Ureteral Reflux/genetics , Child , Child, Preschool , Female , Humans , Infant , Joint Instability/diagnosis , Male , Mutation , PedigreeABSTRACT
BACKGROUND: Mutations in podocin (NPHS2) are the most common cause of childhood onset autosomal recessive steroid-resistant nephrotic syndrome (SRNS). The disease is characterized by early-onset proteinuria, resistance to immunosuppressive therapy and rapid progression to end-stage renal disease. Compound heterozygous changes involving the podocin variant R229Q combined with another pathogenic mutation have been associated with a mild phenotype with disease onset often in adulthood. METHODS: We screened 19 families with early-onset SRNS for mutations in NPHS2 and WT1 and identified four disease-causing mutations (three in NPHS2 and one in WT1) prior to planned whole-exome sequencing. RESULTS: We describe two families with three individuals presenting in childhood who are compound heterozygous for R229Q and one other pathogenic NPHS2 mutation, either L327F or A297V. One child presented at age 4 years (A297V plus R229Q) and the other two at age 13 (L327F plus R229Q), one with steadily deteriorating renal function. CONCLUSIONS: These cases highlight the phenotypic variability associated with the NPHS2 R229Q variant plus pathogenic mutation. Individuals may present with early aggressive disease.
ABSTRACT
PURPOSE: Controversy exists regarding the use of continuous antibiotic prophylaxis vs observation in the management of children with vesicoureteral reflux. The reported effectiveness of continuous antibiotic prophylaxis in children with reflux varies widely. We determined whether the aggregated evidence supports use of continuous antibiotic prophylaxis in children with vesicoureteral reflux. MATERIALS AND METHODS: We searched the Cochrane Controlled Trials Register, clinicaltrials.gov, MEDLINE(®), EMBASE(®), Google Scholar and recently presented meeting abstracts for reports in any language. Bibliographies of included studies were then hand searched for any missed articles. The study protocol was prospectively registered at PROSPERO (No. CRD42014009639). Reports were assessed and data abstracted in duplicate, with differences resolved by consensus. Risk of bias was assessed using standardized instruments. RESULTS: We identified 1,547 studies, of which 8 are included in the meta-analysis. Pooled results demonstrated that continuous antibiotic prophylaxis significantly reduced the risk of recurrent febrile or symptomatic urinary tract infection (pooled OR 0.63, 95% CI 0.42-0.96) but, if urinary tract infection occurred, increased the risk of antibiotic resistant organism (pooled OR 8.75, 95% CI 3.52-21.73). A decrease in new renal scarring was not associated with continuous antibiotic prophylaxis use. Adverse events were similar between the 2 groups. Significant heterogeneity existed between studies (I(2) 50%, p = 0.03), specifically between those trials with significant risk of bias (eg unclear protocol descriptions and/or lack of blinding). CONCLUSIONS: Compared to no treatment, continuous antibiotic prophylaxis significantly reduced the risk of febrile and symptomatic urinary tract infections in children with vesicoureteral reflux, although it increased the risk of infection due to antibiotic resistant bacteria. Continuous antibiotic prophylaxis did not significantly impact the occurrence of new renal scarring or reported adverse events.
Subject(s)
Antibiotic Prophylaxis , Urinary Tract Infections/etiology , Urinary Tract Infections/prevention & control , Vesico-Ureteral Reflux/complications , HumansABSTRACT
Steroid-sensitive nephrotic syndrome (SSNS) accounts for >80% of cases of nephrotic syndrome in childhood. However, the etiology and pathogenesis of SSNS remain obscure. Hypothesizing that coding variation may underlie SSNS risk, we conducted an exome array association study of SSNS. We enrolled a discovery set of 363 persons (214 South Asian children with SSNS and 149 controls) and genotyped them using the Illumina HumanExome Beadchip. Four common single nucleotide polymorphisms (SNPs) in HLA-DQA1 and HLA-DQB1 (rs1129740, rs9273349, rs1071630, and rs1140343) were significantly associated with SSNS at or near the Bonferroni-adjusted P value for the number of single variants that were tested (odds ratio, 2.11; 95% confidence interval, 1.56 to 2.86; P=1.68×10(-6) (Fisher exact test). Two of these SNPs-the missense variants C34Y (rs1129740) and F41S (rs1071630) in HLA-DQA1-were replicated in an independent cohort of children of white European ancestry with SSNS (100 cases and ≤589 controls; P=1.42×10(-17)). In the rare variant gene set-based analysis, the best signal was found in PLCG2 (P=7.825×10(-5)). In conclusion, this exome array study identified HLA-DQA1 and PLCG2 missense coding variants as candidate loci for SSNS. The finding of a MHC class II locus underlying SSNS risk suggests a major role for immune response in the pathogenesis of SSNS.
Subject(s)
Genetic Predisposition to Disease/epidemiology , HLA-DQ alpha-Chains/genetics , Nephrotic Syndrome/epidemiology , Nephrotic Syndrome/genetics , Phospholipase C gamma/genetics , Steroids/therapeutic use , Age Distribution , Age of Onset , Alleles , Case-Control Studies , Child , Child, Preschool , Cohort Studies , Female , Genotype , Humans , Incidence , Male , Mutation, Missense , Nephrotic Syndrome/drug therapy , Sex Distribution , Sri Lanka/epidemiologyABSTRACT
Primary vesicoureteral reflux (VUR) is the most common congenital anomaly of the kidney and the urinary tract, and it is a major risk factor for pyelonephritic scarring and CKD in children. Although twin studies support the heritability of VUR, specific genetic causes remain elusive. We performed a sequential genome-wide linkage study and whole-exome sequencing in a family with hereditary VUR. We obtained a significant multipoint parametric logarithm of odds score of 3.3 on chromosome 6p, and whole-exome sequencing identified a deleterious heterozygous mutation (T3257I) in the gene encoding tenascin XB (TNXB in 6p21.3). This mutation segregated with disease in the affected family as well as with a pathogenic G1331R change in another family. Fibroblast cell lines carrying the T3257I mutation exhibited a reduction in both cell motility and phosphorylated focal adhesion kinase expression, suggesting a defect in the focal adhesions that link the cell cytoplasm to the extracellular matrix. Immunohistochemical studies revealed that the human uroepithelial lining of the ureterovesical junction expresses TNXB, suggesting that TNXB may be important for generating tensile forces that close the ureterovesical junction during voiding. Taken together, these results suggest that mutations in TNXB can cause hereditary VUR.
Subject(s)
Cell Adhesion/genetics , Cell Movement/genetics , Kidney/pathology , Tenascin/genetics , Urinary Tract/abnormalities , Vesico-Ureteral Reflux/genetics , Female , Genome-Wide Association Study , Heterozygote , Humans , Kidney/metabolism , Male , Mutation , Pedigree , Sequence Analysis, DNA , Tenascin/metabolism , Urinary Tract/metabolism , Urinary Tract/pathology , Vesico-Ureteral Reflux/metabolism , Vesico-Ureteral Reflux/pathologyABSTRACT
BACKGROUND: Mutations of the CYP24A1 gene, which encodes the 1,25-dihydroxyvitamin D-24-hydroxylase cytochrome P450, Cyp24A1, are predicted to result in elevated 1,25-dihydroxyvitamin D concentrations, hypercalcemia, hypercalciuria, nephrolithiasis, and bone disease. Treatment of hypercalcemia associated with CYP24A1 gene mutations has not been described. METHODS: The genetic basis of a syndrome in a 44-yr-old Caucasian male characterized by intermittent hypercalcemia, hypercalciuria, elevated serum 1,25-dihydroxyvitamin D, undetectable serum 24,25-dihydroxyvitamin D, metabolically active nephrolithiasis, and reduced bone mineral density of the lumbar spine was examined. Sequencing of the CYP24A1 gene and biochemical and genetic analysis of seven family members in three generations was carried out. Because of hypercalcemia, hypercalciuria, and metabolically active nephrolithiasis, the patient was treated with a cytochrome 3A inhibitor, ketoconazole, 200 mg orally every 8 h, for 2 months. RESULTS: The sequence of the CYP24A1 gene showed two canonical splice junction mutations in the proband. Analysis of family members showed a phenotype associated one or both mutations, suggesting autosomal dominant transmission with partial penetrance of the trait. After therapy with ketoconazole, statistically significant reductions in previously elevated urinary calcium into the normal range were noted. Previously elevated serum 1,25-dihydroxyvitamin D and calcium concentrations decreased, and previously decreased PTH concentrations increased into the normal range, but the differences were not statistically significant. CONCLUSIONS: In a syndrome characterized by intermittent hypercalcemia, hypercalciuria, elevated 1,25-dihydroxyvitamin D, undetectable 24,25-dihydroxyvitamin D concentrations, splice junction mutations of the CYP24A1 gene, and autosomal dominant transmission of the trait, treatment with ketoconazole is useful in reducing urinary calcium.
Subject(s)
14-alpha Demethylase Inhibitors/therapeutic use , Calcitriol/blood , Hypercalcemia/drug therapy , Hypercalciuria/drug therapy , Ketoconazole/therapeutic use , Steroid Hydroxylases/genetics , Adult , Genotype , Humans , Hypercalcemia/blood , Hypercalcemia/genetics , Hypercalciuria/blood , Hypercalciuria/genetics , Male , Mutation , Syndrome , Treatment Outcome , Vitamin D3 24-HydroxylaseABSTRACT
Surface-enhanced Raman Scattering (SERS) is studied in sub-wavelength metallic gratings on a substrate using a rigorous electromagnetic approach. In the ultraviolet SERS is limited by the metallic dampening, yet enhancements as large as 10(5) are predicted. It is shown that these enhancements are directly linked to the spectral position of the plasmonic band edge of the metal/substrate surface plasmon. A simple methodology is presented for selecting the grating pitch to produce optimal enhancement for a given laser frequency.
Subject(s)
Models, Theoretical , Spectrum Analysis, Raman/instrumentation , Spectrum Analysis, Raman/methods , Surface Plasmon Resonance/instrumentation , Surface Plasmon Resonance/methods , Ultraviolet Rays , Aluminum Oxide/chemistry , Electromagnetic Fields , Lasers , Metals , Surface PropertiesABSTRACT
Hypertension affects one billion people and is a principal reversible risk factor for cardiovascular disease. Pseudohypoaldosteronism type II (PHAII), a rare Mendelian syndrome featuring hypertension, hyperkalaemia and metabolic acidosis, has revealed previously unrecognized physiology orchestrating the balance between renal salt reabsorption and K(+) and H(+) excretion. Here we used exome sequencing to identify mutations in kelch-like 3 (KLHL3) or cullin 3 (CUL3) in PHAII patients from 41 unrelated families. KLHL3 mutations are either recessive or dominant, whereas CUL3 mutations are dominant and predominantly de novo. CUL3 and BTB-domain-containing kelch proteins such as KLHL3 are components of cullin-RING E3 ligase complexes that ubiquitinate substrates bound to kelch propeller domains. Dominant KLHL3 mutations are clustered in short segments within the kelch propeller and BTB domains implicated in substrate and cullin binding, respectively. Diverse CUL3 mutations all result in skipping of exon 9, producing an in-frame deletion. Because dominant KLHL3 and CUL3 mutations both phenocopy recessive loss-of-function KLHL3 mutations, they may abrogate ubiquitination of KLHL3 substrates. Disease features are reversed by thiazide diuretics, which inhibit the Na-Cl cotransporter in the distal nephron of the kidney; KLHL3 and CUL3 are expressed in this location, suggesting a mechanistic link between KLHL3 and CUL3 mutations, increased Na-Cl reabsorption, and disease pathogenesis. These findings demonstrate the utility of exome sequencing in disease gene identification despite the combined complexities of locus heterogeneity, mixed models of transmission and frequent de novo mutation, and establish a fundamental role for KLHL3 and CUL3 in blood pressure, K(+) and pH homeostasis.
Subject(s)
Carrier Proteins/genetics , Cullin Proteins/genetics , Hypertension/genetics , Mutation/genetics , Pseudohypoaldosteronism/genetics , Water-Electrolyte Imbalance/genetics , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Animals , Base Sequence , Blood Pressure/genetics , Carrier Proteins/chemistry , Cohort Studies , Cullin Proteins/chemistry , Electrolytes , Exons/genetics , Female , Gene Expression Profiling , Genes, Dominant/genetics , Genes, Recessive/genetics , Genotype , Homeostasis/genetics , Humans , Hydrogen-Ion Concentration , Hypertension/complications , Hypertension/physiopathology , Male , Mice , Microfilament Proteins , Models, Molecular , Molecular Sequence Data , Phenotype , Potassium/metabolism , Pseudohypoaldosteronism/complications , Pseudohypoaldosteronism/physiopathology , Sodium Chloride/metabolism , Water-Electrolyte Imbalance/complications , Water-Electrolyte Imbalance/physiopathologyABSTRACT
Focal and segmental glomerulosclerosis (FSGS) is an important cause of steroid-resistant nephrotic syndrome in adults and children. It is responsible for 5-20% of all cases of end-stage kidney disease (ESKD) in the United States. The pathogenesis of FSGS has not been fully elucidated; however, data from molecular studies of familial cases in the last two decades suggest that FSGS is a defect of the podocyte. The therapeutic agents available for treatment of FSGS are not very effective and only a small percentage of affected individuals will achieve complete remission. Recent data from molecular biology and molecular genetics has provided insight into the mechanisms of action of old agents and also identification of other novel therapeutic targets. This review focuses on recent advances in the molecular pathogenesis of FSGS and currently available therapeutic agents as well as potential novel therapies.
Subject(s)
Glomerulosclerosis, Focal Segmental/etiology , Glomerulosclerosis, Focal Segmental/therapy , Immunosuppressive Agents/therapeutic use , Kidney/pathology , Stem Cell Transplantation , Genetic Predisposition to Disease , Glomerulosclerosis, Focal Segmental/classification , Glomerulosclerosis, Focal Segmental/pathology , Humans , Podocytes/pathology , Risk Factors , Treatment OutcomeABSTRACT
We theoretically predict and experimentally demonstrate inhibition of linear absorption for phase and group velocity mismatched second- and third-harmonic generation in strongly absorbing materials, GaAs, in particular, at frequencies above the absorption edge. A 100-fs pump pulse tuned to 1300 nm generates 650 and 435 nm second- and third-harmonic pulses that propagate across a 450-microm-thick GaAs substrate without being absorbed. We attribute this to a phase-locking mechanism that causes the pump to trap the harmonics and to impress on them its dispersive properties.
ABSTRACT
Acute interstitial nephritis (AIN) is a known cause of acute renal failure in children. In most instances, drug therapy is the offending agent. Although granuloma formation has been observed in drug-induced interstitial nephritis, it is not a commonly associated manifestation. This is a case of a 15-year-old white female with Tetralogy of Fallot and pulmonary atresia who developed acute renal failure secondary to drug-induced interstitial nephritis and renal granulomas. In addition to interstitial edema with eosinophils and lymphocytes, her renal biopsy showed interstitial granulomas, immune complexes within tubular basement membranes, and the unusual feature of multinucleated giant cells engulfing tubules. Her acute renal failure resolved after the withdrawal of antibiotics and the initiation of intravenous steroid therapy.
Subject(s)
Anti-Bacterial Agents/adverse effects , Cefuroxime/adverse effects , Granuloma/chemically induced , Nephritis, Interstitial/chemically induced , Acute Kidney Injury/drug therapy , Acute Kidney Injury/etiology , Adolescent , Antigen-Antibody Complex/metabolism , Basement Membrane/metabolism , Basement Membrane/pathology , Biopsy , Female , Glucocorticoids/therapeutic use , Granuloma/complications , Granuloma/diagnosis , Humans , Kidney/metabolism , Kidney/pathology , Nephritis, Interstitial/complications , Nephritis, Interstitial/diagnosis , Prednisone/therapeutic useABSTRACT
Sulfur-doped zinc oxide (ZnO) nanowires grown on gold-coated silicon substrates inside a horizontal tube furnace exhibit remarkably strong visible wavelength emission with a quantum efficiency of 30%, an integrated intensity 1600 times stronger than band edge ultraviolet emission, and a spectral distribution that closely matches the dark-adapted human eye response. By comparatively studying sulfur-doped and undoped ZnO micropowders, we clarify how sulfur doping and nanostructuring affect the visible luminescence and the underlying energy transfer mechanisms.
Subject(s)
Luminescence , Luminescent Measurements/instrumentation , Nanostructures/chemistry , Nanostructures/radiation effects , Sulfur/chemistry , Zinc Oxide/chemistry , Zinc Oxide/radiation effects , Equipment Design , Equipment Failure Analysis , Light , Luminescent Measurements/methods , Materials Testing , Molecular Conformation , Nanostructures/ultrastructure , Particle Size , Powders , Spectrometry, Fluorescence , Time FactorsSubject(s)
Health Services Needs and Demand/trends , Health Services Research/trends , Kidney Failure, Chronic/economics , Kidney Failure, Chronic/therapy , Nephrology/economics , Pediatrics/trends , Societies, Medical , Child , Evidence-Based Medicine , Fee Schedules/organization & administration , Humans , Nephrology/methods , Nephrology/trends , Outcome Assessment, Health Care/standards , Pediatrics/methods , Quality Control , Quality of Health Care/trends , Reimbursement Mechanisms/economics , Research Support as Topic/trends , Treatment Outcome , United StatesABSTRACT
The nasal actions of histamine were originally attributed to vascular and neuronal H(1) receptor activation. Recent studies have identified a H(3) receptor that contributes to histamine-induced inflammation via the inhibition of sympathetic activity. There is also evidence that pollen-induced nasal blockage can be treated by H(1) antagonists. However, although desloratadine might offer relief, this is unlikely to be through inhibition of nasal H(1) receptors. Despite evidence of an active H(2) receptor on nasal vasculature, this receptor subtype appears to play only a minor role in nasal inflammation. The activation of H(1) receptors cannot account for all of the acute actions of histamine in the nasal airway.